Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF
- 1 October 2016
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 380 (2) , 577-585
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (1R21CA165039-01A1, 1R01CA181183-01A1)
- National Cancer Institute (1R21CA165039-01A1, 1R01CA181183-01A1)
- American Thyroid Association (1R21CA165039-01A1, 1R01CA181183-01A1)
- Canadian Association of Optometrists (1R21CA165039-01A1, 1R01CA181183-01A1)
This publication has 65 references indexed in Scilit:
- STAT3 negatively regulates thyroid tumorigenesisProceedings of the National Academy of Sciences, 2012
- SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2Journal of Experimental Medicine, 2012
- Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targetsClinical & Experimental Metastasis, 2012
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in miceProceedings of the National Academy of Sciences, 2011
- Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancerSurgery, 2010
- B-RafV600Eand thrombospondin-1 promote thyroid cancer progressionProceedings of the National Academy of Sciences, 2010
- Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sproutingJournal of Experimental Medicine, 2007
- The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cellsJournal of Experimental Medicine, 2006
- Cachexia in cancer patientsNature Reviews Cancer, 2002